These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23148794)

  • 21. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
    Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and significance of CYP2C19*2 and CYP2C19*17 alleles in a New Zealand acute coronary syndrome population.
    Larsen PD; Johnston LR; Holley A; La Flamme AC; Smyth L; Chua EW; Kennedy MA; Harding SA
    Intern Med J; 2015 May; 45(5):537-45. PubMed ID: 25583161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China.
    Wu H; Qian J; Xu J; Sun A; Sun W; Wang Q; Ge J
    Pharmacogenet Genomics; 2012 Dec; 22(12):887-90. PubMed ID: 22990067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of initial clinical presentation on clopidogrel low response.
    Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM; Lemesle G
    Arch Cardiovasc Dis; 2013 Nov; 106(11):593-600. PubMed ID: 24070598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
    Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting.
    Golukhova EZ; Ryabinina MN; Bulaeva NI; Grigorian MV; Kubova MCh; Serebruany VL
    Am J Ther; 2015; 22(3):222-30. PubMed ID: 25946232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome.
    Cuisset T; Quilici J; Cohen W; Fourcade L; Saut N; Pankert M; Gaborit B; Carrieri P; Morange PE; Bonnet JL; Alessi MC
    Am J Cardiol; 2011 Sep; 108(6):760-5. PubMed ID: 21803320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI.
    Zhang HZ; Kim MH; Han JY; Jeong YH
    Platelets; 2014; 25(4):285-91. PubMed ID: 23971745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients.
    Wu H; Qian J; Xu J; Sun A; Sun W; Wang Q; Ge J
    Int J Cardiol; 2013 Apr; 165(1):204-6. PubMed ID: 22974728
    [No Abstract]   [Full Text] [Related]  

  • 34. Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests.
    Gremmel T; Kopp CW; Moertl D; Seidinger D; Koppensteiner R; Panzer S; Mannhalter C; Steiner S
    Thromb Res; 2012 May; 129(5):616-22. PubMed ID: 22154242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
    J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis].
    Chen H; Yan W; Wu XY
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Dec; 30(12):1245-9. PubMed ID: 21302482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
    Paré G; Mehta SR; Yusuf S; Anand SS; Connolly SJ; Hirsh J; Simonsen K; Bhatt DL; Fox KA; Eikelboom JW
    N Engl J Med; 2010 Oct; 363(18):1704-14. PubMed ID: 20979470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clopidogrel in acute coronary syndrome: to genotype or not?
    Storey RF
    Lancet; 2009 Jan; 373(9660):276-8. PubMed ID: 19108882
    [No Abstract]   [Full Text] [Related]  

  • 40. CYP2C19 LOF alleles confer no risk for HTPR but higher risk for recurrent ischemic events in clopidogrel treated elderly ACS patients.
    Yang J; Wang X; Peng L; Zhang L; Li X; Liu J; Zhang Y; Xu Q; Lu C; Chen Y; Yin T
    Int J Cardiol; 2015; 189():225-7. PubMed ID: 25897911
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.